<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04440865</url>
  </required_header>
  <id_info>
    <org_study_id>COLO-GENIUS</org_study_id>
    <nct_id>NCT04440865</nct_id>
  </id_info>
  <brief_title>Impact of Artificial Intelligence Genius® System-assisted Colonoscopy vs. Standard Colonoscopy (COLO-GENIUS)</brief_title>
  <acronym>COLO-GENIUS</acronym>
  <official_title>Impact of Artificial Intelligence Genius® System-assisted Colonoscopy vs. Standard Colonoscopy on Adenoma Detection Rate in Routine Practice: a Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinique Paris-Bercy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinique Paris-Bercy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This controlled-randomized trial compares the artificial intelligence Genius® system assisted&#xD;
      (Genius+) to standard (Genius-) colonoscopy.&#xD;
&#xD;
      The aim of this study was to evaluate the impact of Genius® system on ADR in routine&#xD;
      colonoscopy. The secondary aims will be the impact of Genius® system on polyp detection rate&#xD;
      (PDR), serrated polyp detection rate (SPDR), advanced neoplasia detection rate (ANDR), mean&#xD;
      number of polyps (MNP), polyp type and localization, and operator type (according to basal&#xD;
      ADR).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Any patient seen by gastroenterologists working in the endoscopy unit and meeting the&#xD;
      inclusion criteria may be recruited.&#xD;
&#xD;
      The patient will be offered to participate in the study. The information form as well as the&#xD;
      consent, will be given to the patient for a good understanding of the study and the&#xD;
      investigator in charge of the patient gives all the additional explanations necessary for&#xD;
      this good understanding (but of the study, the course, risks and benefits).&#xD;
&#xD;
      A period of reflection will be left to the patient or his family to make a free decision&#xD;
      whether or not to participate in the study.&#xD;
&#xD;
      After the consent to participate will be signed by the gastroenterologist and the patient,&#xD;
      the patient will be randomized. The use of the Genius® system will depend on the&#xD;
      randomization that will be performed at the start of the colonoscopy.&#xD;
&#xD;
      This randomization will be done in the computer examination room using the randomization&#xD;
      software.&#xD;
&#xD;
      The patient will therefore be randomized into 2 groups:&#xD;
&#xD;
      Arm 1- Standard colonoscopy Arm 2- Colonoscopy assisted by Genius® system&#xD;
&#xD;
      A comparison of the two groups standard colonoscopy vs colonoscopy assisted by Genius® system&#xD;
      will be made as following:&#xD;
&#xD;
      A-Main criterion:&#xD;
&#xD;
      - Adenoma detection rate (ADR)&#xD;
&#xD;
      B-Secondary criteria:&#xD;
&#xD;
      Polyps detection rate (PDR) Proximal serrated polyps detection rate (PSPDR) Neoplasia&#xD;
      detection rate (NDR) Mean number of polyps (MNP) Mean number of adenomas (MNA) Factors&#xD;
      associated with ADR&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 7, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm 1- Standard colonoscopy Arm 2- Colonoscopy assisted by Genius® system</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adenoma Detection Rate (ADR)</measure>
    <time_frame>1 day</time_frame>
    <description>percentage of colonoscopy with one or more adenoma of the colon</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Advanced Neoplasia Detection Rate (ANDR)</measure>
    <time_frame>1 day</time_frame>
    <description>percentage of colonoscopy with one or more advanced neoplasia of the colon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proximal Serrated Polyp Detection Rate (PSPDR)</measure>
    <time_frame>1 day</time_frame>
    <description>percentage of colonoscopy with one or more serrated polyp of the colon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polyp Detection Rate (PDR)</measure>
    <time_frame>1 day</time_frame>
    <description>percentage of colonoscopy with one or more polyp of the colon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The factors influencing the Adenoma Detection Rate (ADR)</measure>
    <time_frame>1 day</time_frame>
    <description>Withdrawal time (in seconds): time of exploration from the caecum to the anal verge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The factors influencing the Adenoma Detection Rate (ADR)</measure>
    <time_frame>1 day</time_frame>
    <description>Boston scale (0 to 9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach caecum (sec)</measure>
    <time_frame>1 day</time_frame>
    <description>Time to reach caecum from the beginning of the procedure (in seconds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caecal intubation rate (%)</measure>
    <time_frame>1 day</time_frame>
    <description>Caecal intubation rate (complete colonoscopy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity: perforation rate (%)</measure>
    <time_frame>7 days after procedure</time_frame>
    <description>Perforation rates (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity: bleeding rate (%)</measure>
    <time_frame>7 days after procedure</time_frame>
    <description>Bleeding rates (%)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2100</enrollment>
  <condition>Colonic Polyp</condition>
  <condition>Colonoscopy</condition>
  <condition>Artificial Intelligence</condition>
  <condition>Colonic Adenoma</condition>
  <condition>Colonic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm 1- Standard colonoscopy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard colonoscopy is performed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2- Colonoscopy assisted by Genius</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Colonoscopy assisted by Genius artificial intelligence system is performed</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Genius® System-assisted Colonoscopy</intervention_name>
    <description>Genius® Intelligence System is used to assist Colonoscopy</description>
    <arm_group_label>Arm 2- Colonoscopy assisted by Genius</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Colonoscopy</intervention_name>
    <description>Standard Colonoscopy without Genius® Intelligence System is performed</description>
    <arm_group_label>Arm 1- Standard colonoscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient scheduled for total colonoscopic exploration, during the period study&#xD;
&#xD;
          -  Patient over or equal to 18 years&#xD;
&#xD;
          -  ASA 1, ASA 2, ASA 3&#xD;
&#xD;
          -  No participation in another clinical study&#xD;
&#xD;
          -  Certificate of non opposition signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient under 18 years old&#xD;
&#xD;
          -  ASA 4, ASA 5&#xD;
&#xD;
          -  Pregnant woman&#xD;
&#xD;
          -  Patient with coagulation abnormalities preventing polypectomy: prothrombin level &lt;50%,&#xD;
             Platelets &lt;50000 / mm3, effective anti-coagulation in progress, clopidogrel in&#xD;
             progress.&#xD;
&#xD;
          -  Patient referred for resection of a known polyp&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Known colonic stenosis&#xD;
&#xD;
          -  Diverticulitis less than 6 weeks old&#xD;
&#xD;
          -  Patient unable to give consent or protected by law&#xD;
&#xD;
          -  Opposition expressed for inclusion in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Karsenti, MD</last_name>
    <role>Study Director</role>
    <affiliation>Clinique Paris-Bercy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bouchra Benkessou</last_name>
    <phone>0143967812</phone>
    <email>b.benkessou@cliniques-bltparis.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique Paris-Bercy</name>
      <address>
        <city>Charenton-le-Pont</city>
        <zip>94220</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>David Karsenti</last_name>
      <phone>+33143967850</phone>
      <email>karsenti@club-internet.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 18, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2020</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Colonic Polyps</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

